Randomized trial of prolonged low-dose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants

Pediatrics

Volumn 112, Issue 2 I, 2003, Pages 345-350

  Lee, Jiun ^a   Rajadurai, Victor Samuel ^a   Tan, Keng Wee ^a   Wong, Keng Yean ^a   Wong, Ee Hwee ^b   Leong, Joy Yoke Ngan ^b  

^a KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^b Clinical Trials and Epidemiology Research Unit   (Singapore)

Author keywords

Indomethacin; Patent ductus arteriosus; Premature infants; Prolonged; Randomized trial; Very low birth weight

Indexed keywords

CREATININE; INDOMETACIN;

ARTERY LIGATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPONATREMIA; INTESTINE PERFORATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NECROTIZING ENTEROCOLITIS; NEWBORN; OLIGURIA; PATENT DUCTUS ARTERIOSUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH HEMORRHAGE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG ADMINISTRATION SCHEDULE; DUCTUS ARTERIOSUS, PATENT; ECHOCARDIOGRAPHY, DOPPLER; ENTEROCOLITIS, NECROTIZING; FEMALE; HUMANS; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INFANT, VERY LOW BIRTH WEIGHT; MALE;

EID: 0042632587     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.112.2.345     Document Type: Article

References (16)

1. Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr. 1983;102:895-906
2. Hammerman C. Patent ductus arteriosus: clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clin Perinatol. 1995;22:457-479
3. Clyman RI, Chan CY, Mauray F, et al. Permanent anatomic closure of the ductus arteriosus in newborn baboons: the roles of postnatal constriction, hypoxia, and gestation. Pediatr Res. 1999;45:19-29
4. Rennie JM, Cooke RW. Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity. Arch Dis Child. 1991;66:55-58
5. Hammerman C, Aramburo MJ. Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus. J Pediatr. 1990;117:771-776
6. Tammela O, Ojala R, Iivainen T, et al. Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. J Pediatr. 1999;134:552-557
7. Clyman RI. Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. J Pediatr. 1996;128:601-607
8. Kluckow M, Evans N. Early echocardiographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilation. J Pediatr. 1995;127:774-779
9. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am. 1986;33:179-201
10. Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statistics With Confidence. 2nd ed. London, United Kingdom: British Medical Journal Books; 2000
11. Seidner S, Chen Y, Oprysko P, et al. Combined prostaglandin and nitric oxide inhibition produces anatomic remodelling and closure of the ductus arteriosus in the premature newborn baboon. Pediatr Res. 2001;50:365-373
12. Rennie JM, Doyle J, Cooke RW. Early administration of indomethacin to preterm infants. Arch Dis Child. 1986;61:233-238
13. Ojala R, Ala-Houhala M, Ahonen S, et al. Renal follow up of premature infants with and without perinatal indomethacin exposure. Arch Dis Child Fetal Neonatal Ed. 2001;84:F28-F33
14. Meyers R, Alpan G, Lin E, Clyman R. Patent ductus arteriosus, indomethacin, and intestinal distension: effects on intestinal blood flow and oxygen consumption. Pediatr Res. 1991;29:569-574
15. Rajadurai VS, Yu VYH. Intravenous indomethacin therapy in preterm neonates with patent ductus arteriosus. J Pediatr Child Health. 1991;27:370-375
16. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely low birthweight infants. N Engl J Med. 2001;344:1966-1972